Display options
Cite
Shakeri H, Gharesouran J, Fakhrjou A, et al. DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification. EXCLI J. 2016;15:11-20doi: 10.17179/excli2015-485.
Shakeri, H., Gharesouran, J., Fakhrjou, A., Esfahani, A., & Mohaddes Ardebili, S. M. (2016). DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification. EXCLI journal, 1511-20. https://doi.org/10.17179/excli2015-485
Shakeri, Halaleh, et al. "DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification." EXCLI journal vol. 15 (2016): 11-20. doi: https://doi.org/10.17179/excli2015-485
Shakeri H, Gharesouran J, Fakhrjou A, Esfahani A, Mohaddes Ardebili SM. DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification. EXCLI J. 2016 Jan 11;15:11-20. doi: 10.17179/excli2015-485. eCollection 2016. PMID: 27065772; PMCID: PMC4822054.
Copy Download .nbib Format: NLM
Share it on

EXCLI J. 2016 Jan 11;15:11-20. doi: 10.17179/excli2015-485. eCollection 2016.

DNA methylation assessment as a prognostic factor in invasive breast cancer using methylation-specific multiplex ligation dependent probe amplification.

EXCLI journal

Halaleh Shakeri, Jalal Gharesouran, Ashraf Fakhrjou, Ali Esfahani, Seyyed Mojtaba Mohaddes Ardebili

Affiliations

  1. Hematology & Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Biochemistry and Clinical Laboratories, Division of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  2. Department of Biochemistry and Clinical Laboratories, Division of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  3. Department of Pathology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  4. Hematology & Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

PMID: 27065772 PMCID: PMC4822054 DOI: 10.17179/excli2015-485

Abstract

DNA methylation of promoter regions is a common molecular mechanism for inactivation of tumor suppressor genes that participates in carcinogenesis. Determining the methylation status of genes in cancer and their association with clinical features play an essential role in early diagnosis, prognosis and determine appropriate treatment for patients. The purpose of the present study was to evaluate the methylation of tumor suppressor genes in patients with invasive ductal carcinoma (IDC). Furthermore, we evaluated the association between clinical parameters and DNA methylation as a biomarker in diagnostic IDC patients. The methylation-specific multiplex ligation dependent probe amplification (MS-MLPA) assay was used to analyze the methylation profile of 24 genes in formalin-fixed paraffin embedded (FFPE) tissue samples from 75 patients with IDC. Each of the patients showed a distinctive methylation profile. We observed higher methylation in the RASSF1 (48 %), CDH13 (44 %) and GSTP1 (36 %) genes. Some of the methylated genes were associated with clinical features. Methylation of GSTP1 (P=0.028) and RASSF1 (P=0.012) were related with lymph node metastasis. Methylation of GSTP1 (P=0.005) was associated with high histological grade. Moreover, concurrent methylation of GSTP1 and CDH13 was observed in IDC patients (p<0.001). Hierarchical cluster analysis based on the methylation profile revealed two main clusters of patients, the highly methylated cluster being significantly associated with high histological grade and lymph node metastasis. The results of this study indicate that the methylation status of RASSF1 and CDH13 and GSTP1 can be a prognostic marker to better management of IDC patients.

Keywords: IDC; MS-MLPA; breast cancer; methylation; tumor suppressor genes

References

  1. Clin Transl Oncol. 2016 Apr;18(4):391-7 - PubMed
  2. Virchows Arch. 2013 Jan;462(1):47-56 - PubMed
  3. Histopathology. 2010 Sep;57(3):363-70 - PubMed
  4. Biochem Biophys Res Commun. 2013 Mar 22;432(4):632-7 - PubMed
  5. Histol Histopathol. 2005 Apr;20(2):645-63 - PubMed
  6. Biochem Biophys Res Commun. 2014 Dec 5;455(1-2):70-83 - PubMed
  7. Oncol Rep. 2012 May;27(5):1630-8 - PubMed
  8. Nucleic Acids Res. 2005 Aug 16;33(14):e128 - PubMed
  9. Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2694-700 - PubMed
  10. Chin J Cancer. 2013 Jan;32(1):12-20 - PubMed
  11. Breast Cancer Res Treat. 2012 Jan;131(1):197-205 - PubMed
  12. Int J Cancer. 2001 Oct 15;94(2):212-7 - PubMed
  13. Cell Oncol. 2009;31(6):487-500 - PubMed
  14. Med Sci Monit. 2014 Sep 04;20:1572-7 - PubMed
  15. Breast Cancer Res Treat. 2006 Nov;100(2):169-76 - PubMed
  16. J Mol Diagn. 2012 Nov;14 (6):613-22 - PubMed
  17. Sci Transl Med. 2011 Mar 23;3(75):75ra25 - PubMed
  18. Histopathology. 1991 Nov;19(5):403-10 - PubMed
  19. Br J Cancer. 2001 Jul 6;85(1):69-73 - PubMed
  20. EXCLI J. 2014 Aug 26;13:954-76 - PubMed
  21. Epigenomics. 2015;7(2):187-99 - PubMed
  22. Breast Cancer Res. 2013 Jun 28;15(3):206 - PubMed
  23. Cancer Causes Control. 2009 Nov;20(9):1539-50 - PubMed
  24. Clin Cancer Res. 2005 Jan 1;11(1):166-72 - PubMed
  25. J Clin Oncol. 2008 Jul 1;26(19):3153-8 - PubMed
  26. Cancer Res. 2001 Apr 15;61(8):3225-9 - PubMed
  27. Obstet Gynecol Int. 2012;2012:602720 - PubMed
  28. Breast Cancer Res. 2007;9(4):R57 - PubMed
  29. BMC Cancer. 2012 Jun 13;12:243 - PubMed
  30. Life Sci. 2007 Jul 4;81(4):280-7 - PubMed
  31. Biol Res. 2014 Mar 26;47:3 - PubMed
  32. J Pathol. 2011 Oct;225(2):222-31 - PubMed
  33. Oncologist. 2004;9(6):606-16 - PubMed
  34. Medicina (Kaunas). 2013;49(2):78-83 - PubMed
  35. Brief Bioinform. 2014 Nov;15(6):929-41 - PubMed
  36. Arch Pathol Lab Med. 2004 Nov;128(11):1251-1256 - PubMed
  37. Cancer Res. 2001 Jun 1;61(11):4556-60 - PubMed
  38. Clin Cancer Res. 2004 Aug 15;10(16):5349-54 - PubMed
  39. Exp Ther Med. 2012 Dec;4(6):1097-1103 - PubMed
  40. Int J Mol Sci. 2013 Jul 18;14(7):15029-58 - PubMed
  41. Clin Cancer Res. 2005 Mar 15;11(6):2156-62 - PubMed
  42. Iran Biomed J. 2009 Oct;13(4):199-206 - PubMed

Publication Types